Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study).

Background: Antiplatelet therapies, including prasugrel, are a cornerstone in the treatment of ST-segment elevation myocardial infarction (STEMI), but are associated with a bleeding risk. This risk has been evaluated in randomized trials, but few data on real-world patients are available.

Aim: To evaluate prasugrel safety in real-world patients with STEMI.

Gender differences in presentation, management and inhospital outcome in patients with ST-segment elevation myocardial infarction: data from 5000 patients included in the ORBI prospective French regional registry.

Background: Gender differences in presentation, management and outcome in patients with ST-segment elevation myocardial infarction (STEMI) have been reported.

Aim: To determine whether female gender is associated with higher inhospital mortality.

Methods: Data from ORBI, a regional STEMI registry of 5 years' standing, were analysed.

[Vascular complications at the femoral access: impact of the percutaneous closure device Perclose].

Introduction: Vascular complications at the femoral access site is an important factor of morbidity. The aims of this study were to evaluate the efficacy and safety of the percutaneous closure device (Perclose) during interventional cardiology procedures.

Patients And Methods: All patients with percutaneous closure of the femoral access site by the Perclose system in 2010 were included.

[Very late bare-metal stent thrombosis 10 years after the implantation: a case report].

Very late thrombosis occurring after bare-metal stent (BMS) implantation is a rare complication. It differs from very late thrombosis of drug-eluting stents in terms of both frequency and pathophysiological mechanism. We report a case of very late stent thrombosis of a bare-metal stent 10 years after his implantation for treatment of a myocardial infarction.